NeuroMET
Neurodegeneration is an incurable, debilitating process. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common neurodegenerative diseases (NDD). Both involve the build up of specific proteins in the brain and subsequent neurodegeneration leading to physical and mental impairment including dementia.
The NeuroMET project, funded under the European Metrology Programme for Innovation and Research (EMPIR), addressed the challenges associated with diagnosis of AD.
NeuroMET1
About the project
The NeuroMET1 project, developed reference measurement systems to support the major NDD patient needs including less invasive, more accurate diagnostic measurement, and improved treatment and anxiety monitoring.
Link to publishable summary Link to publishable report Link to summary posterThe consortium
NeuroMET2
About the project
The NeuroMET2 project, built upon the results of the preceding NeuroMET project and its unique patient cohort to apply metrological principles of AD diagnosis.
The most promising NeuroMET minimally invasive methods for early diagnosis of AD were advanced through longitudinal studies and transferred to clinical settings. The project also developed novel approaches and reference measurement procedures to address the current measurement challenges of early neurodegenerative disease diagnostics and therapies.
Link to publishable summary Link to publishable report Project summary posterThe consortium
NeuroMET events and announcements
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EURAMET. Neither the European Union nor the granting authority can be held responsible for them.
This project has received funding from the EMPIR programme co-financed by the Participating States and from the European Union’s Horizon 2020 research and innovation programme.
Get in touch
If you’re interested in exploring partnership opportunities with the NML or learning more about our measurement capabilities, we’d love to hear from you.